119 related articles for article (PubMed ID: 15110133)
1. Intrahepatic arterial administration of low-dose methotrexate in patients with severe hepatic graft-versus-host disease: an open-label, uncontrolled trial.
Bloom AI; Shapira MY; Or R; Sasson T; Resnick IB; Zilberman I; Verstandig A; Aker M; Slavin S; Muszkat M
Clin Ther; 2004 Mar; 26(3):407-14. PubMed ID: 15110133
[TBL] [Abstract][Full Text] [Related]
2. Intra-arterial catheter directed therapy for severe graft-versus-host disease.
Shapira MY; Bloom AI; Or R; Sasson T; Nagler A; Resnick IB; Aker M; Zilberman I; Slavin S; Verstanding A
Br J Haematol; 2002 Dec; 119(3):760-4. PubMed ID: 12437655
[TBL] [Abstract][Full Text] [Related]
3. Combination of tacrolimus, methotrexate, and methylprednisolone prevents acute but not chronic graft-versus-host disease in unrelated bone marrow transplantation.
Ogawa H; Soma T; Hosen N; Tatekawa T; Tsuboi A; Oji Y; Tamaki H; Kawakami M; Ikegame K; Murakami M; Fujioka T; Kim EH; Oka Y; Sugiyama H
Transplantation; 2002 Jul; 74(2):236-43. PubMed ID: 12151737
[TBL] [Abstract][Full Text] [Related]
4. The outcome of unrelated donor bone marrow transplantation in patients with hematologic malignancies using tacrolimus (FK506) and low dose methotrexate for graft-versus-host disease prophylaxis.
Devine SM; Geller RB; Lin LB; Dix SP; Holland HK; Maurer D; O'Toole K; Keller J; Connaghan DG; Heffner LT; Hillyer CD; Rodey GE; Winton EF; Maher RM; Fitzsimmons WE; Wingard JR
Biol Blood Marrow Transplant; 1997 Apr; 3(1):25-33. PubMed ID: 9209738
[TBL] [Abstract][Full Text] [Related]
5. First-line therapy for chronic graft-versus-host disease that includes low-dose methotrexate is associated with a high response rate.
Wang Y; Xu LP; Liu DH; Chen H; Chen YH; Han W; Liu KY; Huang XJ
Biol Blood Marrow Transplant; 2009 Apr; 15(4):505-11. PubMed ID: 19285639
[TBL] [Abstract][Full Text] [Related]
6. Substitution of methotrexate with corticosteroid for acute graft-versus-host disease prevention in transplanted patients who develop methotrexate toxicity.
Kim SY; Kim AR; Yoon SY; Cho YH; Lee MH
Ann Hematol; 2016 Feb; 95(3):483-91. PubMed ID: 26658911
[TBL] [Abstract][Full Text] [Related]
7. Folinic acid administration after MTX GVHD prophylaxis in pediatric allo-SCT.
Hudspeth MP; Heath TS; Chiuzan C; Garrett-Mayer E; Nista E; Burton L; Ragucci D
Bone Marrow Transplant; 2013 Jan; 48(1):46-9. PubMed ID: 22609886
[TBL] [Abstract][Full Text] [Related]
8. Cyclosporine combined with methylprednisolone or methotrexate in prophylaxis of moderate to severe acute graft-versus-host disease.
Gondo H; Harada M; Taniguchi S; Akashi K; Hayashi S; Teshima T; Takamatsu Y; Eto T; Nagafuji K; Yamasaki K
Bone Marrow Transplant; 1993 Nov; 12(5):437-41. PubMed ID: 8298553
[TBL] [Abstract][Full Text] [Related]
9. Low-dose methotrexate may preserve a stronger antileukemic effect than that of cyclosporine after modified donor lymphocyte infusion in unmanipulated haploidentical HSCT.
Yan CH; Xu LP; Liu DH; Chen H; Wang Y; Wang JZ; Wang FR; Han W; Liu KY; Huang XJ
Clin Transplant; 2015 Jul; 29(7):594-605. PubMed ID: 25969866
[TBL] [Abstract][Full Text] [Related]
10. [Prophylaxis with FK-506 for graft-versus-host disease after transplantation of bone marrow from unrelated donors].
Hamazaki T; Yagi K; Inoue M; Sakata N; Okamura T; Yasui M; Sasabe M; Kishimoto T; Inoue A; Kawa K
Rinsho Ketsueki; 2000 May; 41(5):430-6. PubMed ID: 10879106
[TBL] [Abstract][Full Text] [Related]
11. Low-dose MTX for the treatment of acute and chronic graft-versus-host disease in children.
Inagaki J; Nagatoshi Y; Hatano M; Isomura N; Sakiyama M; Okamura J
Bone Marrow Transplant; 2008 Mar; 41(6):571-7. PubMed ID: 18026150
[TBL] [Abstract][Full Text] [Related]
12. Graft-versus-host disease prophylaxis with anti-T-cell monoclonal antibody OKT3, prednisone and methotrexate in allogeneic bone-marrow transplantation.
Filipovich AH; Krawczak CL; Kersey JH; McGlave P; Ramsay NK; Goldman A; Goldstein G
Br J Haematol; 1985 May; 60(1):143-52. PubMed ID: 3890926
[TBL] [Abstract][Full Text] [Related]
13. Prevention of graft-versus-host disease in high risk patients by depletion of CD4+ and reduction of CD8+ lymphocytes in the marrow graft.
Herrera C; Torres A; García-Castellano JM; Roman J; Martin C; Serrano J; Falcon M; Alvarez MA; Gomez P; Martinez F
Bone Marrow Transplant; 1999 Mar; 23(5):443-50. PubMed ID: 10100557
[TBL] [Abstract][Full Text] [Related]
14. Omission of day +11 methotrexate after allogeneic bone marrow transplantation is associated with increased risk of severe acute graft-versus-host disease.
Kumar S; Wolf RC; Chen MG; Gastineau DA; Gertz MA; Inwards DJ; Lacy MQ; Tefferi A; Litzow MR
Bone Marrow Transplant; 2002 Aug; 30(3):161-5. PubMed ID: 12189534
[TBL] [Abstract][Full Text] [Related]
15. [Unrelated donor stem cell transplantation in children: low toxicity using a GvHD-prophylaxis regimen with CSA, MTX, metronidazole,iv-immunoglobulin and ATG].
Graf Finckenstein F; Zabelina T; Dürken M; Dahlke J; Kröger N; Krüger W; Janka-Schaub G; Erttmann R; Zander AR; Kabisch H
Klin Padiatr; 2002; 214(4):206-11. PubMed ID: 12165903
[TBL] [Abstract][Full Text] [Related]
16. Tacrolimus and methotrexate for the prophylaxis of acute graft-versus-host disease in allogeneic bone marrow transplantation in patients with hematologic malignancies.
Uberti JP; Silver SM; Adams PT; Jacobson P; Scalzo A; Ratanatharathorn V
Bone Marrow Transplant; 1997 Jun; 19(12):1233-8. PubMed ID: 9208118
[TBL] [Abstract][Full Text] [Related]
17. Unmanipulated HLA 2-3 antigen-mismatched (haploidentical) bone marrow transplantation using only pharmacological GVHD prophylaxis.
Ogawa H; Ikegame K; Kaida K; Yoshihara S; Fujioka T; Taniguchi Y; Tamaki H; Inoue T; Hasei H; Iiboshi Y; Tazuke Y; Kawakami M; Kim EH; Soma T; Inoue T; Kawase I
Exp Hematol; 2008 Jan; 36(1):1-8. PubMed ID: 17920757
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of low-dose methotrexate for pediatric patients with steroid-refractory acute graft-versus-host disease after hematopoietic stem cell transplantation.
Inagaki J; Fukano R; Kodama Y; Nishimura M; Shimokawa M; Okamura J
Ann Hematol; 2014 Apr; 93(4):645-51. PubMed ID: 24146233
[TBL] [Abstract][Full Text] [Related]
19. Graft-versus-host-disease prophylaxis for matched unrelated donor bone marrow transplantation: comparison between cyclosporine-methotrexate and cyclosporine-methotrexate-methylprednisolone.
Leelasiri A; Greer JP; Stein RS; Goodman S; Brandt SA; Edwards JR; Wolff SN
Bone Marrow Transplant; 1995 Mar; 15(3):401-5. PubMed ID: 7599565
[TBL] [Abstract][Full Text] [Related]
20. [Comparison study on treatment of acute graft-versus-host disease with low-dose methotrexate in combination with low-dose methylprednisolone or standard-dose methylprednisolone].
Wang J; Xu LP; Liu DH; Liu KY; Chen H; Chen YH; Han W; Wang Y; Huang XJ
Zhonghua Xue Ye Xue Za Zhi; 2011 Aug; 32(8):512-5. PubMed ID: 22338171
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
